Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma

被引:18
|
作者
Matrone, Antonio [1 ]
Gambale, Carla [1 ]
Prete, Alessandro [1 ]
Piaggi, Paolo [2 ,3 ]
Cappagli, Virginia [1 ]
Bottici, Valeria [1 ]
Romei, Cristina [1 ]
Ciampi, Raffaele [1 ]
Torregrossa, Liborio [4 ]
De Napoli, Luigi [5 ]
Molinaro, Eleonora [1 ]
Materazzi, Gabriele [5 ]
Basolo, Fulvio [4 ]
Elisei, Rossella [1 ]
机构
[1] Univ Hosp Pisa, Dept Clin & Expt Med, Endocrine Unit, Via Paradisa 2, I-56124 Pisa, Italy
[2] Natl Inst Diabet & Digest & Kidney Dis, NIH, Phoenix, AZ 85016 USA
[3] Univ Pisa, Dept Informat Engn, I-56124 Pisa, Italy
[4] Univ Hosp Pisa, Dept Surg Med Mol Pathol & Crit Area, I-56124 Pisa, Italy
[5] Univ Hosp Pisa, Dept Surg Med Mol Pathol & Crit Area, Unit Endocrine Surg, I-56124 Pisa, Italy
关键词
medullary thyroid carcinoma; sporadic; age; distant metastasis; death rate; PROGNOSTIC-FACTORS; RET PROTOONCOGENE; CANCER; MUTATIONS; SURVIVAL; CARRIERS; HEALTH; MEN;
D O I
10.3390/cancers13010094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The clinical behavior of medullary thyroid carcinoma is heterogeneous and can be influenced by several clinical, biochemical and molecular factors. The role of age as a prognostic factor remains controversial. In our cohort of 432 sporadic medullary thyroid carcinoma, no differences in histologic features at diagnosis and in number and type of therapies performed during the follow-up were detected when dividing the patients according to age (< and >= 65 years). Younger patients had a longer follow-up and survival time, compared to the older patients. However, in dead patients, no differences in the aggressiveness of the disease at presentation and treatments performed during the follow-up were found between the two age groups. Sporadic medullary thyroid carcinoma (MTC) is a rare malignancy with a heterogeneous clinical course. Several potential prognostic factors have been investigated, but the impact of some of these is controversial, such as age at diagnosis. We evaluated the data of 432 sporadic MTC patients followed-up for a median of 7.4 years. Patients were divided and compared according to their age at diagnosis in group A (<65 years-n = 338, 78.2%) and group B (>= 65 years-n = 94, 21.8%). No differences were detected between the two groups. Median follow-up time was significantly longer in patients <65 than >= 65 years. We observed 41 (9.5%) cancer-related death events. The death rate was similar between the two age groups. However, the Kaplan Meier curve showed a longer survival time for younger patients compared to older patients [HR 2.5 (CI 95%: 1.27-4.94), p < 0.01]. Nevertheless, no differences in the aggressiveness of the disease at presentation and in the number and type of treatments performed were found in the two subgroups of dead patients. In patients with sporadic MTC, age at diagnosis did not correlate with any clinical and pathological features. Cancer-related death events are similar in older and younger patients, but survival time is longer in the younger.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] Controversies in the surgical management of sporadic medullary thyroid carcinoma
    Fussey, Jonathan Mark
    Bradley, Patrick J.
    Smith, Joel A.
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2020, 28 (02): : 68 - 73
  • [32] Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma
    Oliver Gimm
    Thomas Sutter
    Henning Dralle
    Journal of Cancer Research and Clinical Oncology, 2001, 127 : 156 - 165
  • [33] MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome
    Mian, Caterina
    Pennelli, Gianmaria
    Fassan, Matteo
    Balistreri, Mariangela
    Barollo, Susi
    Cavedon, Elisabetta
    Galuppini, Francesca
    Pizzi, Marco
    Vianello, Federica
    Pelizzo, Maria Rosa
    Girelli, Maria Elisa
    Rugge, Massimo
    Opocher, Giuseppe
    THYROID, 2012, 22 (09) : 890 - 896
  • [34] The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review
    Fussey, Jonathan Mark
    Vaidya, Bijay
    Kim, Dae
    Clark, Jonathan
    Ellard, Sian
    Smith, Joel Anthony
    CLINICAL ENDOCRINOLOGY, 2019, 91 (06) : 697 - 707
  • [35] Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study
    Hirsch, Dania
    Twito, Orit
    Levy, Sigal
    Bachar, Gideon
    Robenshtok, Eyal
    Gross, David J.
    Mazeh, Haggi
    Benbassat, Carlos
    Grozinsky-Glasberg, Simona
    THYROID, 2018, 28 (03) : 369 - 376
  • [36] Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study
    Essig, Garth F., Jr.
    Porter, Kyle
    Schneider, David
    Arpaia, Debora
    Lindsey, Susan C.
    Busonero, Giulia
    Fineberg, Daniel
    Fruci, Barbara
    Boelaert, Kristien
    Smit, Johannes W.
    Meijer, Johannes Arnoldus Anthonius
    Duntas, Leonidas H.
    Sharma, Neil
    Costante, Giuseppe
    Filetti, Sebastiano
    Sippel, Rebecca S.
    Biondi, Bernadette
    Topliss, Duncan J.
    Pacini, Furio
    Maciel, Rui M. B.
    Walz, Patrick C.
    Kloos, Richard T.
    THYROID, 2016, 26 (11) : 1563 - 1572
  • [37] Reevaluating the Significance of Multifocality in Sporadic Medullary Thyroid Carcinoma (MTC)
    Grubbs, E.
    Nieves-Munoz, F.
    Hu, M.
    Feng, L.
    Perrier, N. D.
    Lee, J. E.
    Cote, G.
    Williams, M. D.
    Gagel, R.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S98 - S99
  • [38] RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population
    Costa, P
    Domingues, R
    Sobrinho, LG
    Bugalho, MJ
    ENDOCRINE, 2005, 27 (03) : 239 - 243
  • [39] MEDULLARY CARCINOMA OF THYROID - BIOLOGIC BEHAVIOR OF THE SPORADIC AND FAMILIAL NEOPLASM
    KAKUDO, K
    CARNEY, JA
    SIZEMORE, GW
    CANCER, 1985, 55 (12) : 2818 - 2821
  • [40] Evaluation of Grade in a Genotyped Sporadic Medullary Thyroid Carcinoma Cohort
    Najdawi, Fedaa
    Barletta, Justine
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 367 - 367